文献速递消化道肿瘤与早癌消化内镜

基线结肠镜低危或高危腺瘤与无腺瘤者异时性结直肠癌及死亡风险的系统综述与Meta分析

Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis.
PubMed 文献 · Gastroenterology · 2021-01-29

该系统综述与Meta分析纳入12项研究共510,019例患者,比较基线结肠镜无腺瘤、低危腺瘤(LRA)和高危腺瘤(HRA)者异时性结直肠癌(CRC)及CRC相关死亡风险。结果显示HRA者CRC及死亡风险显著高于无腺瘤者,而LRA者风险很低、与无腺瘤者相当,提示LRA随访应与无腺瘤者相同。

要点

  • HRA者异时性CRC风险显著高于无腺瘤者(OR 2.92)和LRA者(OR 2.35)。
  • LRA者CRC风险仅略高于无腺瘤者(OR 1.26),CRC相关死亡无显著差异。
  • LRA者随访策略应与无腺瘤者相同。

核心结论

  • HRA者异时性CRC及CRC相关死亡风险显著高于无腺瘤者,而LRA者风险很低、与无腺瘤者相当。
  • 基线结肠镜检出LRA者的随访应与无腺瘤者相同。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Google Scholar和Cochrane数据库。
  • 最终纳入12项研究,共510,019例患者,平均年龄59.2±2.6岁,55%男性,平均随访8.5±3.3年。

主要发现

  • 每10,000人年CRC发生率:LRA者4.5 vs 无腺瘤者3.4(OR 1.26,95%CI 1.06-1.51,I2=0)。
  • 每10,000人年CRC发生率:HRA者13.8 vs 无腺瘤者3.4(OR 2.92,95%CI 2.31-3.69,I2=0)。
  • 每10,000人年CRC发生率:HRA者13.81 vs LRA者4.5(OR 2.35,95%CI 1.72-3.20,I2=55%)。
  • 每10,000人年CRC相关死亡率:LRA者 vs 无腺瘤者无显著差异(OR 1.15,95%CI 0.76-1.74,I2=0)。
  • 每10,000人年CRC相关死亡率:HRA者显著高于LRA者(OR 2.48,95%CI 1.30-4.75,I2=38%)和无腺瘤者(OR 2.69,95%CI 1.87-3.87,I2=0)。

临床怎么用

  • 基线结肠镜检出LRA者可按无腺瘤者进行随访。
  • HRA者需更密切随访以监测异时性CRC及死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The risk of metachronous colorectal cancer (CRC) among patients with no adenomas, low-risk adenomas (LRAs), or high-risk adenomas (HRAs), detected at index colonoscopy, is unclear. We performed a systematic review and meta-analysis to compare incidence rates of metachronous CRC and CRC-related mortality after a baseline colonoscopy for each group. METHODS: We searched the PubMed, Embase, Google Scholar, and Cochrane databases for studies that reported the incidence of CRC and adenoma characteristics after colonoscopy. The primary outcome was odds of metachronous CRC and CRC-related mortality per 10,000 person-years of follow-up after baseline colonoscopy for all the groups. RESULTS: Our final analysis included 12 studies with 510,019 patients (mean age, 59.2 ± 2.6 years; 55% male; mean duration of follow up, 8.5 ± 3.3 years). The incidence of CRC per 10,000 person-years was marginally higher for patients with LRAs compared to those with no adenomas (4.5 vs 3.4; odds ratio [OR], 1.26; 95% CI, 1.06-1.51; I2=0), but significantly higher for patients with HRAs compared to those with no adenoma ( 13.8 vs 3.4; odds ratio [OR], 2.92; 95% CI, 2.31-3.69; I2=0 ) and patients with HRAs compared to LRAs (13.81 vs 4.5; OR, 2.35; 95% CI, 1.72-3.20; I2=55%). However, the CRC-related mortality per 10,000 person-years did not differ significantly for patients with LRAs compared to no adenomas (OR, 1.15; 95% CI, 0.76-1.74; I2=0) but was significantly higher in persons with HRAs compared with LRAs (OR, 2.48; 95% CI, 1.30-4.75; I2=38%) and no adenomas (OR, 2.69; 95% CI, 1.87-3.87; I2=0). CONCLUSIONS: The results of this systematic review and meta-analysis demonstrate that the risk of metachronous CRC and mortality is significantly higher for patients with HRAs, but this risk is very low in patients with LRAs, comparable to patients with no adenomas. Follow-up of patients with LRAs detected at index colonoscopy should be the same as for persons with no adenomas.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Duvvuri A, Chandrasekar VT, Srinivasan S, et al. Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology. 2021. PMID: 33524401. doi:10.1053/j.gastro.2021.01.214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。